Dr. Hanns Lochmüller Recipient of the Dr. George Karpati Award for Researcher of the Year

The NMD4C are excited to share that the network’s lead investigator Dr. Hanns Lochmüller is the recipient of Muscular Dystrophy Canada’s Dr. George Karpati Award for Researcher of the Year! This prestigious award is presented annually to an exemplary neuromuscular clinician or researcher who has made a significant contribution to neuromuscular research, or the advancement of care of people with neuromuscular disorders. 

Dr. Lochmuller is a neurologist and clinical academic specializing in genetic neuromuscular disorders and rare disease in Ottawa, and supports the neuromuscular community in many ways: He is the lead Principal Investigator of the Neuromuscular Disease Network for Canada (NMD4C); He is an active member of MDC’s Medical and Scientific Advisory Committee (MSAC); He reviews research grants, speaks at various webinars, contributes to publications (over 30 in 2021 alone!), serves as a role model for early career clinicians and scientists, as well as serving as an academic lead on MDC’s Economic Cost of Living Study.

Dr. Lochmuller is a champion for the patient community and is strongly committed to bringing patients and patient organizations into equal partnerships. He has been instrumental in ensuring individuals impacted by NMDs and their family members are at the center of advances in the neuromuscular community in Canada and abroad.

Read more about Dr. Lochmüller’s accomplishments and research here, or visit the Lochmüller Lab website.

Hanns_KarpatiAward

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.